{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.27","upperLimit":"0.69","value":"0.48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"A comfirmed Complete Response (CR) is defined as a CR noted as the objective status on 2 consecutive evaluations. To be categorized as a CR, patients must exhibit the following:\\>\n\n* Negative immunofixation of serum and urine c, and\\>\n* Disappearance of any soft tissue plasmacytoma, and\\>\n* \\<5% plasma cells in Bone Marrow, and\\>\n* If the only measurable disease is the serum free light chain (FLC), a normal FLC ratio.\\>\n\nWe are reporting the proportion of patients achieving a CR or higher divided by the total number of evaluable patients.\\> Exact binomial 95% confidence intervals for the true success proportion will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Sonidegib, Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"Of the 28 patients registered, one cancelled prior to treatment and 1 was ineligible due to protocol violation. Therefore 26 patients were used in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Complete Response, Assessed Using the International Myeloma Working Group (IMWG) Uniform Response Criteria","type":"PRIMARY","unitOfMeasure":"proportion of patients"}